CC BY 4.0 · Synlett
DOI: 10.1055/a-2186-1485
cluster
Japan/Netherlands Gratama Workshop

Practical Site-Selective Oxidation of Glycosides with Palladium(II) Acetate/Neocuproine

Niels R. M. Reintjens
,
Imke M. A. Bartels
,
Nittert Marinus
,
Sarina C. Massmann
,
Daan V. Bunt
,
Marthe T. C. Walvoort
,
,
I.M.A.B. and S.C.M. thank ARC-CBBC for funding. N.M. thanks NWO (project number 718.016.001) for funding.
 


Abstract

The palladium-catalyzed oxidation of the secondary C(3) hydroxy group of glycopyranosides has set a mark in the selective modification of unprotected carbohydrates. The preformed catalyst [(neocuproine)PdOAc]2(OTf)2 oxidizes di- and oligosaccharides, as well as monosaccharides. Here, we provide a more convenient protocol for this reaction in which the Pd catalyst is formed in situ from Pd(OAc)2 and neocuproine in methanol at 50 °C. Together with a simplified product isolation, this protocol was applied to a series of mono- and disaccharides, and has been applied on a 10 gram scale. The protocol is also valuable as a screening method to determine whether more-extensive studies using the preformed catalyst are worthwhile.


#

The carbonyl group plays the central role in synthetic organic chemistry.[1] [2] [3] [4] To modify carbohydrates, it is therefore of preeminent importance that hydroxy groups in carbohydrates can be oxidized in a site-selective manner to the corresponding carbonyl group. This can be effected by means of protecting-group strategies in which a hydroxy group is singled out and subsequently oxidized. An alternative is the site-selective oxidation of nonprotected carbohydrates. Well-established is the oxidation of the primary hydroxy group in glycopyranoses by using a bulky nitrosonium species generated from TEMPO or a related compound with hypochlorite, or by using [bis(acetoxy)iodo]benzene or anodic oxidation.[5–10] The regioselectivity of this oxidation reaction is clearly based on steric hindrance.

Site-selective oxidation of the secondary hydroxy groups in unprotected carbohydrates is considerably more challenging,[11] [12] but significant progress has been made over the past ten years. Waymouth and co-workers were able to selectively oxidize glycerol with the catalyst [(neocuproine)PdOAc]2(OTf)2 and 1,4-benzoquinone (BQ) or oxygen as a terminal oxidant (Scheme [1]A).[13] [14] In 2013, our group used this catalyst to exploit the higher reactivity of the C(3) hydroxy group to permit its selective oxidation in glucosides and, later, in oligosaccharides and even glucopeptides (Scheme [1]B).[15] [16] [17] [18] Waymouth’s group has also shown that oxygen can be used as the oxidant (Scheme [1]C),[19] whereas we were able to simplify the product-purification process by carrying out the oxidation of methyl α-ᴅ-glucopyranoside (1) to the 3-ketoglucose 2 in methanol on a five-gram scale (Scheme [1]D).[20]

Zoom Image
Scheme 1 Palladium-catalyzed oxidation. DCBQ = 2,6-dichloro-1,4-benzoquinone, BQ = benzoquinone, neocuproine = 2,9-dimethyl-1,10-phenanthroline.

Other approaches for the selective oxidation of 1,2-diols make use of chelating agents such as boronic acids[21] [22] or organotin reagents[23–25] in combination with an oxidant. Recently, Kaspar and Kudova investigated the use of more-classical oxidation reagents to achieve selective oxidation of 1,2-diols in steroids.[26] Although it was possible to achieve the selective oxidation of hydroxy groups at different positions in the steroid, no selectivity was observed for 1,2-diols.

Our group has exploited the keto functionality of unprotected ketosaccharides in the synthesis of rare sugars[27] and, in further modifications, to allow their use in chemical biology, for example, through the introduction of an allyl or an alkyne handle, exocyclic and endocyclic epoxides, an amine or a chloride, and recently, a thiol moiety.[28] [29] [30] [31]

Despite all these illustrations of the versatility and applicability of Waymouth’s catalyst in carbohydrate oxidation, its incorporation in the toolbox of the carbohydrate chemist has been slow. The main reason is probably that the catalyst is not commercially available and has to be prepared. This forms a barrier to applying the method to novel substrates without a guarantee of success. It would be highly desirable to have at hand a straightforward protocol to test the palladium-catalyzed oxidation reaction to decide on its suitability for chemical-biology or glycochemistry applications. A second reason is the laborious purification of the highly polar carbohydrates, so a protocol avoiding column chromatography would also be welcomed.

We reasoned that by using commercially available Pd(OAc)2 and neocuproine (2,9-dimethyl-1,10-phenanthroline), a catalyst might be prepared in situ, and that this system, although potentially less active and selective, would form a versatile screening system to determine whether substrates are suitable and could provide access to ketosaccharides.

Before the advent of [(neocuproine)PdOAc]2(OTf)2, it had already been shown that secondary alcohols could be oxidized with (neocuproine)Pd(OAc)2 at high temperatures.[32] This bisacetate catalyst has been applied with various solvents and with several oxidants such as O2/air[33] [34] or a combination of benzoquinone and electrochemistry.[35] It had also been shown that ligandless Pd(OAc)2 was also effective in some cases.[36] [37] Lemaire’s group combined these methods by preparing (neocuproine)Pd(OAc)2 in situ to selectively oxidize fatty-acid-derived 1,2-diols.[38] These approaches, however, required a high temperature, which is problematic for sensitive substrates and, in addition, carbohydrates are deactivated substrates for oxidation.

We therefore decided to prepare (neocuproine)Pd(OAc)2 catalyst in situ and to study whether, in combination with a suitable solvent and temperature, it could act as a suitable screening catalyst for a variety of carbohydrate substrates.

We first investigated whether (neocuproine)Pd(OAc)2 was able to oxidize glucosides. The catalytic activities of [(neocuproine)PdOAc]2(OTf)2 and (neocuproine)Pd(OAc)2 are dependent on the solvent.[32] [33] Dimeric [(neocuproine)PdOAc]2(OTf)2 dissociates in solution to the active monomeric species. Diol substrates readily coordinate to the active form of [(neocuproine)PdOAc]2(OTf)2, which results in a 325-fold higher turnover frequency (TOF) in acetonitrile compared with the bisacetate catalyst (neocuproine)Pd(OAc)2.[33] Notably, however, a high catalytic activity has been reported for (neocuproine)Pd(OAc)2 in protic solvents.[32] [34] [39] This observation is highly relevant because unprotected carbohydrates do not dissolve well in acetonitrile, but are reasonably soluble in protic solvents such as methanol.

Table 1 Oxidation of Glucoside 1 in 9:1 Acetonitrile–H2O or Methanol with Catalysts 3 and 4

Pd catalyst

Yield (%)

TONa

TOFb

MeCNc

MeOH

MeCNc

MeOH

MeCNc

MeOH

3

92

93

46

47

29

77

4

41

54

21

27

5

12

a The turnover number (TON) was calculated by dividing the conversion after 24 h by the mol% of [Pd].

b The turnover frequency (TOF) was calculated by dividing the conversion after 0.5 h by the mol% of [Pd] and the reaction time. See the Supporting Information (SI) Tables S1 and S2 for the results at all time points.

c MeCN–H2O (9:1 v/v) was used to completely dissolve 1.

To assess the effect of the solvent on the activity of [(neocuproine)PdOAc]2(OTf)2 (3; Table [1]) and [(neocuproine)PdOAc]2(OTf)2 (4), we performed the oxidation of methyl α-ᴅ-glucopyranoside (1) in 9:1 v/v acetonitrile–water and in methanol (Table [1]).[40] [41] In line with previous studies on the oxidation of 2-heptanol and glycerol,[33,39] 3 showed higher turnover frequencies, and it turned out to be the more active in methanol. Although the oxidation reaction with the bisacetate catalyst 4 was considerably slower than that with 3, the TOF almost doubled when methanol was used instead of acetonitrile–water, indicating that oxidation of glucosides with the bisacetate catalyst 4 is facilitated by a protic polar solvent (Table [1]). The origin of the higher activity of catalyst 4 in methanol was not studied in detail, but we hypothesize that it is caused by differences in the dissociation constant of the acetate ligand. The pKa of acetic acid is considerably higher in acetonitrile (pK a = 23.5)[42] than in methanol (pK a = 9.63).[43] We reason that the acetate anion dissociates much more readily in methanol than in acetonitrile and, after dissociation of acetate, the substrate or the solvent can coordinate to the vacant site.[32] Methanol thus facilitates a rapid equilibrium between the inactive palladium acetate complex and the active substrate-bound catalyst.

Having identified methanol as a solvent and preprepared (neocuproine)Pd(OAc)2 (4) as a suitable catalyst system for the oxidation of 1, we subsequently focused our attention on the in-situ-prepared catalyst 4. We were pleased to note that overnight reaction at room temperature, provided partial conversion of glucoside 1 (SI, Table S3).

In attempts to achieve full conversion, we screened various solvents (MeOH, MeOH–MeCN, HFIP, TFE, MeOH/water) and temperatures (room temperature and 50 °C). With Pd(OAc)2 (0.05 equiv), neocuproine (0.05 equiv), and benzoquinone (1.05 equiv) in MeOH (0.2 M) at 50 °C overnight, a near full conversion was achieved, and these conditions were selected for further study.

A simplified product-purification method was designed to ensure the general applicability of the procedure. After concentrating the reaction mixture in vacuo and adding water, the hydroquinone and neocuproine were removed by washing with diethyl ether. Filtration of the aqueous layer through syringe filters of 0.45 μm (twice) and 0.1 μm (once) removed palladium black and polymerized benzoquinone/hydroquinone. Subsequent lyophilization provided the product in >90% purity. With these optimized oxidation and purification methods in hand, 1 was oxidized on a 10-gram scale and produced the 3-ketoglucoside 2 in quantitative yield.

To explore the scope of this procedure, various gluco-configured glycosides were oxidized, including a thioglucopyranoside, various protected glucopyranosides, a xylopyranoside, and glucuronopyranoside (Figure [1]).[44] The corresponding ketosaccharides 613 [45] [46] [47] [48] were isolated in high yields, with the exception of 7. Some products contained trace amounts of starting material, which was not removed by filtration. The moderate yield of 7 was due to its greater solubility in diethyl ether. For the synthesis of 1012, 1.5 equivalents of benzoquinone were used, because 1.05 equivalents led to incomplete conversion. Compound 13 was purified by column chromatography because of its low solubility in water.

Zoom Image
Figure 1 Oxidation of gluco-configured substrates. Reaction conditions: substrate (1 mmol), Pd(OAc)2 (0.05 equiv), neocuproine (0.05 equiv), BQ (1.05 equiv), 0.2 M in MeOH, 50 °C, 18 h. a BQ (1.5 equiv). b After 4 h, an additional 0.5 equivalents of BQ were added. c Yield reported in the literature.[15] [29] [49] [50]

Our study continued with the disaccharides cellobiose and maltose. Regioselective oxidation of methyl β-cellobioside proceeded smoothly, and 14 was isolated in 62% yield, which was slightly higher than the previously reported yield.[15] The tert-butylbenzyl β-maltoside 15, on the other hand, proved to be a more challenging substrate: NMR analysis showed that several byproducts were formed, and purification by column chromatography gave 15 in only 27% yield. Oxidation of the Type 2 diabetes drug dapagliflozin[50] [51] completed our study on gluco-configured substrates, and the 3-ketosaccharide 16 [52] was obtained in 62% yield.

The scope was expanded with substrates possessing a non-glucose configuration. As shown previously, substrates such as mannose and galactose are prone to overoxidation and rearrangements, and provide moderate yields with 3.[49] Indeed, attempts to oxidize methyl l-rhamnopyranoside, methyl d-mannopyranoside, and methyl d-galactopyranoside, as well as TIPS-protected methyl d-mannopyranoside (17; Scheme [2]) led to complex mixtures of compounds, precluding the isolation of the desired ketosaccharides (see SI). We conclude, therefore, that for these and related compounds, the in-situ-formed catalyst in methanol is suitable to determine whether oxidation occurs, whereas catalyst 3 should subsequently be employed to prepare the desired products.[19] [49]

Zoom Image
Scheme 2 Reaction conditions a: Pd(OAc)2 (0.05 equiv), neocuproine (0.05 equiv), BQ (1.05 equiv), 0.2 M in MeOH, 50 °C. Isolated yields are reported. a Yield reported in the literature.[49]

It was noticed that next that the products of non-gluco-configured monosaccharides, as well as several oxidized C-glycosides, can be quite sensitive to overoxidation and rearrangement (Scheme [2]). The oxidation of puerarin (19) with Pd-catalyst 3 has been reported by Nakamura et al. to give 3-ketopuerarin in 70% yield.[53] With the current in-situ-prepared catalyst, a mixture of 20 [54] and 21 was obtained instead of the desired C(3)-keto saccharide. These products are probably formed by migration of the keto functionality from C(3) to C(2), followed by a rearrangement reaction, because a migration of 3-ketopuerarin was observed by Nakamura et al., and the formation of such rearranged products from β-glycosides has been observed before by us.[49] Oxidation of glycoside 22 provided the desired product 23 [55] in 32% yield together with the 2-keto saccharide 24 [56] in 9% yield. The latter is probably formed through an intramolecular deprotonation of the C(2) position by adventitiously formed phenolate.

In conclusion, the catalyst prepared in situ from Pd(OAc)2 and neocuproine in methanol proved to be a suitable catalyst system for rapid screening of the C(3)-selective oxidation of carbohydrates. A straightforward purification protocol that avoids column chromatography permits rapid isolation of the products. For gluco-configured substrates, high yields are obtained and the reaction can be readily scaled up. The sensitivity of some substrates to overoxidation gives lower yields or mixtures of products. Nevertheless, even for these substrates, the protocol functions as a suitable and rapid screening method to determine whether it is worth preparing the Waymouth catalyst for the oxidation of a particular substrate. This protocol should lead to more-widespread application of the site-selective modification of unprotected carbohydrates and, in addition, is not limited to this substrate class, as shown by the oxidation of C-glycosides.


#

Conflict of Interest

The authors declare no conflict of interest.

Supporting Information

  • References and Notes

  • 1 Seebach D. Angew. Chem. Int. Ed. 2011; 50: 96
  • 2 Tojo G, Fernández MI. Oxidation of Alcohols to Aldehydes and Ketones: A Guide to Current Common Practice. Springer; New York: 2006: 255
  • 3 Xu C, Zhang C, Li H, Zhao X, Song L, Li X. Catal. Surv. Asia 2016; 20: 13
  • 4 Modern Oxidation Methods . Bäckvall J.-E. Wiley-VCH; Weinheim: 2004
  • 5 Furukawa K, Shibuya M, Yamamoto Y. Org. Lett. 2015; 17: 2282
  • 6 Zhao M, Li J, Mano E, Song Z, Tschaen DM, Grabowski EJ. J, Reider PJ. J. Org. Chem. 1999; 64: 2564
  • 7 Epp JB, Widlanski TS. J. Org. Chem. 1999; 64: 293
  • 8 Shibuya M, Sato T, Tomizawa M, Iwabuchi Y. Chem. Commun. 2009; 1739
  • 9 Lee W, Youn J.-H, Kang SH. Chem. Commun. 2013; 49: 5231
  • 10 Schämann M, Schäfer HJ. Eur. J. Org. Chem. 2003; 351
  • 11 Eisink N, Minnaard A, Witte M. Synthesis 2017; 49: 822
  • 12 Marinus N, Eisink NN. H. M, Reintjens NR. M, Dijkstra RS, Havenith RW. A, Minnaard AJ, Witte MD. Chem. Eur. J. 2023; e202300318
  • 13 Painter RM, Pearson DM, Waymouth RM. Angew. Chem. Int. Ed. 2010; 49: 9456
  • 14 Chung K, Banik SM, De Crisci AG, Pearson DM, Blake TR, Olsson JV, Ingram AJ, Zare RN, Waymouth RM. J. Am. Chem. Soc. 2013; 135: 7593
  • 15 Jäger M, Hartmann M, de Vries JG, Minnaard AJ. Angew. Chem. Int. Ed. 2013; 52: 7809
  • 16 Eisink NN. H. M, Lohse J, Witte MD, Minnaard AJ. Org. Biomol. Chem. 2016; 14: 4859
  • 17 Reintjens NR. M, Yakovlieva L, Marinus N, Hekelaar J, Nuti F, Papini AM, Witte MD, Minnaard AJ, Walvoort MT. C. Eur. J. Org. Chem. 2022; 2022: e202200677
  • 18 Wan IC, Hamlin TA, Eisink NN. H. M, Marinus N, Boer C, Vis CA, Codée JD. C, Witte MD, Minnaard AJ, Bickelhaupt FM. Eur. J. Org. Chem. 2021; 2021: 632
  • 19 Chung K, Waymouth RM. ACS Catal. 2016; 6: 4653
  • 20 Marinus N, Walvoort MT. C, Witte MD, Minnaard AJ, van Dijk HM. In Carbohydrate Chemistry: Proven Synthetic Methods, Vol. 5, Chap. 16 Wrodnigg T. M., Stütz A., CRC Press: Boca Raton, 2021
  • 21 William JM, Kuriyama M, Onomura O. Adv. Synth. Catal. 2014; 356: 934
  • 22 Feng L, Zhang S, Sun X, Dong A, Chen Q. J. Mater. Sci. 2018; 53: 15025
  • 23 Maki T, Iikawa S, Mogami G, Harasawa H, Matsumura Y, Onomura O. Chem. Eur. J. 2009; 15: 5364
  • 24 William JM, Kuriyama M, Onomura O. RSC Adv. 2013; 3: 19247
  • 25 Muramatsu W. Org. Lett. 2014; 16: 4846
  • 26 Kaspar M, Kudova E. J. Org. Chem. 2022; 87: 9157
  • 27 Zhang J, Eisink NN. H. M, Witte MD, Minnaard AJ. J. Org. Chem. 2019; 84: 516
  • 28 Marinus N, Tahiri N, Duca M, Mouthaan LM. C. M, Bianca S, van den Noort M, Poolman B, Witte MD, Minnaard AJ. Org. Lett. 2020; 22: 5622
  • 29 Zhang J, Reintjens NR. M, Dhineshkumar J, Witte MD, Minnaard AJ. Org. Lett. 2022; 24: 5339
  • 30 Reintjens NR. M, Witte MD, Minnaard AJ. Org. Biomol. Chem. 2023; 21: 5098
  • 31 Ahmadian-Moghaddam M, Reintjens NR. M, Witte MD, Minnaard AJ. Eur. J. Org. Chem. 2023; 26: e202300281
  • 32 ten Brink G.-J, Arends IW. C. E, Hoogenraad M, Verspui G, Sheldon RA. Adv. Synth. Catal. 2003; 345: 1341
  • 33 Conley NR, Labios LA, Pearson DM, McCrory CC. L, Waymouth RM. Organometallics 2007; 26: 5447
  • 34 Bailie DS, Clendenning GM. A, McNamee L, Muldoon MJ. Chem. Commun. 2010; 46: 7238
  • 35 Lybaert J, Tehrani KA, De Wael K. Electrochim. Acta 2017; 247: 685
  • 36 Amatore C, Cammoun C, Jutand A. Synlett 2007; 2173
  • 37 Dornan LM, Muldoon MJ. Catal. Sci. Technol. 2015; 5: 1428
  • 38 Vu ND, Guicheret B, Duguet N, Métay E, Lemaire M. Green Chem. 2017; 19: 3390
  • 39 Wang H, Vu ND, Chen G.-R, Métay E, Duguet N, Lemaire M. Green Chem. 2021; 23: 1154
  • 40 Because of the low solubility of 1 in acetonitrile, we used a 9:1 (v/v) mixture of acetonitrile and water.
  • 41 To a stock solution of methyl α-d-glucopyranoside (1; 45 mg, 0.23 mmol, 1 equiv) and BQ (26 mg, 0.24 mmol, 1.05 equiv) in MeOH (0.1 M) or 9:1 MeCN–H2O (0.1 M) was added catalyst 3 (5 mg, 5 μmol, 2 mol%) or 4 (2 mg, 5 μmol, 2 mol%), and the mixture was stirred for 24 h at rt under air. A portion of the mixture was diluted with CD3OD and analyzed by 1H NMR. The conversion was calculated by dividing the product integral by the sum of the product and starting material integrals. The TON was calculated by dividing the conversion by the mol% [Pd]. The TOF was calculated by using the conversion after 0.5 h by dividing the TON by the reaction time.
  • 42 Kütt A, Tshepelevitsh S, Saame J, Lõkov M, Kaljurand I, Selberg S, Leito I. Eur. J. Org. Chem. 2021; 2021: 1407
  • 43 Miguel EL. M, Silva PL, Pliego JR. J. Phys. Chem. B 2014; 118: 5730
  • 44 Compounds 6–16; General ProcedureBQ (114 mg, 1.05 mmol, 1.05 equiv), neocuproine (10.5 mg, 50 μmol, 5 mol%), and Pd(OAc)2 (11.2 mg, 50 μmol, 5 mol%) were added to a solution of the appropriate substrate (1.0 mmol, 1 equiv) in MeOH (0.2 M). The reactions were monitored by 1H NMR analysis of a 50 μL portion of the reaction mixture diluted with CD3OD. After stirring overnight, the mixture was concentrated in vacuo and the residue was dissolved in H2O (15 mL; Milli-Q), and the solution was washed with Et2O (2 × 30 mL). The aqueous layer was filtered twice through a 1.0 μm pore-size syringe filter and once through a 0.45 μm pore-size syringe filter, then concentrated in vacuo.
  • 45 Characterization data for 8: amorphous solid; yield: 0.14 g, 0.69 mmol (77%). 1H NMR (400 MHz, CD3OD): d = 5.39 (d, J = 4.2 Hz, 1 H), 4.20–4.14 (m, 1 H), 3.95 (dt, J = 12.4, 6.2 Hz, 1 H), 3.89–3.77 (m, 3 H), 2.88 (ddd, J = 13.9, 4.6, 1.1 Hz, 1 H), 2.43 (dd, J = 13.9, 0.9 Hz, 1 H), 1.15 (dd, J = 12.2, 6.2 Hz, 6 H). 13C NMR (101 MHz, CD3OD): d = 207.6, 97.9, 76.6, 74.2, 70.0, 62.6, 47.1, 23.5, 21.4. HRMS(ESI–): m/z [M–H]– calcd for C9H15O5: 203.0925; found: 203.0925.
  • 46 Characterization data for 11: amorphous solid; yield: 0.15 g, 0.85 mmol (85%) [+ 20 mg (0.11 mmol) starting material]. 1H NMR (400 MHz, CD3OD): δ = 4.99 (d, J = 4.4 Hz, 1 H), 4.42 (dd, J = 4.4, 1.5 Hz, 1 H), 3.89 (dd, J = 9.4, 1.4 Hz, 1 H), 3.76–3.68 (m, 1 H), 3.38 (s, 4 H), 1.39 (d, J = 6.2 Hz, 3 H). 13C NMR (101 MHz, CD3OD): δ = 206.5, 103.6, 78.8, 76.1, 72.0, 55.7, 18.9. HRMS(ESI): m/z [M–H] calcd for C7H11O5: 175.0612; found: 175.0612.
  • 47 Characterization data for 12: amorphous solid; yield: 0.15 g 0.74 mmol (85%) [+ starting material: 15 mg (7 μmol)]. 1H NMR (400 MHz, CD3OD): δ = 5.11 (d, J = 4.2 Hz, 1 H), 4.49 (dd, J = 4.1, 1.2 Hz, 1 H), 4.45 (d, J = 9.8 Hz, 1 H), 4.08 (d, J = 9.8 Hz, 1 H), 3.44 (d, J = 4.8 Hz, 3 H). 13C NMR (101 MHz, CD3OD) δ = 205.4, 104.3, 76.0, 75.0, 75.0, 56.2. HRMS (ESI): m/z [M–H] calcd for C7H9O7: 205.0354; found: 205.0354.
  • 48 Characterization data for 13: amorphous solid; yield: 0.22 g, 0.73 mmol (73%). 1H NMR (400 MHz, CD3OD): δ = 5.08 (d, J = 4.3 Hz, 1 H), 4.41 (dd, J = 4.2, 1.2 Hz, 1 H), 4.27 (dd, J = 9.7, 1.2 Hz, 1 H), 4.06–3.92 (m, 2 H), 3.68 (ddd, J = 9.7, 4.4, 2.0 Hz, 1 H), 3.43 (s, 3 H), 0.98 (s, 9 H), 0.16 (s, 6 H). 13C NMR (101 MHz, CD3OD): δ = 207.0, 103.7, 76.8, 76.0, 73.2, 63.9, 55.6, 26.4, –5.1, –5.2. HRMS (ESI): m/z [M + Na]+ calcd for C13H26NaO6Si: 329.1391; found: 329.1391.
  • 49 Eisink NN. H. M, Witte MD, Minnaard AJ. ACS Catal. 2017; 7: 1438
  • 50 Zhiyuan Z, Shaoqiang H, Zhaolan Z, Yanning SU, Yan RE. N. WO 2016041470 2016
  • 51 Balkanski S. Pharmacia (Sofia, Bulg.) 2021; 68: 591
  • 52 Characterization data for 16: colorless oil; yield: 0.25 g, 0.62 mmol (62%). 1H NMR (400 MHz, CD3OD): δ = 7.42–7.35 (m, 3 H), 7.09 (d, J = 8.6 Hz, 2 H), 6.79 (d, J = 8.6 Hz, 2 H), 4.39 (d, J = 10.0 Hz, 1 H), 4.23 (s, 2 H), 4.11–3.90 (m, 5 H), 3.82 (dd, J = 12.1, 4.7 Hz, 1 H), 3.49 (ddd, J = 10.0, 4.8, 1.9 Hz, 1 H), 1.35 (t, J = 7.0 Hz, 4 H). 13C NMR (101 MHz, CD3OD): δ = 208.4, 158.9, 140.1, 139.3, 135.0, 132.8, 131.7, 130.8, 130.3, 128.0, 115.4, 85.2, 84.7, 78.6, 74.0, 64.4, 62.9, 39.2, 15.2. HRMS(ESI): m/z [M–H] calcd for C21H22ClO6: 405.1110 and 407.1081; found: 405.1105 and 407.1076.
  • 53 Nakamura K, Zhu S, Komatsu K, Hattori M, Iwashima M. Biol. Pharm. Bull. 2019; 42: 417
  • 54 Characterization data for 20: isolated as an oil, together with 21; yield: 51 mg, 0.11 mmol (48%). 1H NMR (400 MHz, CD3OD): δ = 8.13 (s, 1 H), 8.03–7.96 (m, 1 H), 7.41–7.31 (m, 2 H), 6.91–6.82 (m, 3 H), 5.80 (s, 1 H), 4.79 (d, J = 9.3 Hz, 1 H), 4.09–3.92 (m, 2 H), 3.91–3.85 (m, 1 H), 3.20 (s, 3 H). 13C NMR (101 MHz, CD3OD): δ = 177.8, 173.5, 162.9, 158.7, 156.2, 154.2, 131.3, 127.9, 125.8, 124.0, 117.9, 117.5, 116.2, 110.1, 87.6, 86.1, 83.3, 74.1, 59.6, 52.6. HRMS (ESI): m/z [M–H] calcd for C22H21O10 [M+H]+: 445.1129; found: 445.1124.
  • 55 Characterization data for 23: isolated as an oil together with 24; yield: 96 mg, 0.32 mmol (32%). 1H NMR (400 MHz, CD3OD): δ = 8.44 (d, J = 2.7 Hz, 1 H), 8.10 (dd, J = 9.0, 2.8 Hz, 1 H), 6.94 (d, J = 9.0 Hz, 1 H), 4.82 (d, J = 10.0 Hz, 1 H), 4.54 (dd, J = 10.0, 1.6 Hz, 1 H), 4.44 (dd, J = 10.0, 1.5 Hz, 1 H), 3.95 (dd, J = 12.3, 1.9 Hz, 1 H), 3.84 (dd, J = 12.3, 4.8 Hz, 1 H), 3.55 (ddd, J = 10.0, 4.8, 2.0 Hz, 1 H). 13C NMR (101 MHz, CD3OD): δ = 208.4, 163.0, 141.9, 127.3, 126.4, 126.0, 116.6, 84.8, 78.8, 78.1, 74.0, 62.9. HRMS (ESI): m/z [M–H] calcd for C12H12NO8: 298.0568; found: 298.0563.
  • 56 Characterization data for 24: isolated as an oil together with 23; yield: 26 mg, 90 μmol (9%). 1H NMR (400 MHz, CD3OD): δ = 8.22 (d, J = 2.8 Hz, 1 H), 8.08 (dd, J = 8.9, 2.8 Hz, 1 H), 6.88 (d, J = 9.1 Hz, 1 H), 5.37 (s, 1 H), 4.43 (d, J = 9.3 Hz, 1 H), 4.02 (d, J = 10.3 Hz, 1 H), 3.94–3.79 (m, 2 H), 3.68 (t, J = 9.4 Hz, 1 H). 13C NMR (101 MHz, CD3OD): δ = 202.1, 162.0, 141.8, 126.2, 125.2, 124.6, 115.5, 82.7, 81.3, 78.6, 76.2, 62.7. HRMS (ESI): m/z [M–H] calcd for C12H12NO8: 298.0568; found: 298.0564.

Corresponding Authors

Martin D. Witte
Stratingh Institute for Chemistry, University of Groningen
Groningen 9747 AG, Nijenborgh 7
The Netherlands   
Adriaan J. Minnaard
Stratingh Institute for Chemistry, University of Groningen
Groningen 9747 AG, Nijenborgh 7
The Netherlands   

Publication History

Received: 12 September 2023

Accepted after revision: 04 October 2023

Accepted Manuscript online:
04 October 2023

Article published online:
09 November 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References and Notes

  • 1 Seebach D. Angew. Chem. Int. Ed. 2011; 50: 96
  • 2 Tojo G, Fernández MI. Oxidation of Alcohols to Aldehydes and Ketones: A Guide to Current Common Practice. Springer; New York: 2006: 255
  • 3 Xu C, Zhang C, Li H, Zhao X, Song L, Li X. Catal. Surv. Asia 2016; 20: 13
  • 4 Modern Oxidation Methods . Bäckvall J.-E. Wiley-VCH; Weinheim: 2004
  • 5 Furukawa K, Shibuya M, Yamamoto Y. Org. Lett. 2015; 17: 2282
  • 6 Zhao M, Li J, Mano E, Song Z, Tschaen DM, Grabowski EJ. J, Reider PJ. J. Org. Chem. 1999; 64: 2564
  • 7 Epp JB, Widlanski TS. J. Org. Chem. 1999; 64: 293
  • 8 Shibuya M, Sato T, Tomizawa M, Iwabuchi Y. Chem. Commun. 2009; 1739
  • 9 Lee W, Youn J.-H, Kang SH. Chem. Commun. 2013; 49: 5231
  • 10 Schämann M, Schäfer HJ. Eur. J. Org. Chem. 2003; 351
  • 11 Eisink N, Minnaard A, Witte M. Synthesis 2017; 49: 822
  • 12 Marinus N, Eisink NN. H. M, Reintjens NR. M, Dijkstra RS, Havenith RW. A, Minnaard AJ, Witte MD. Chem. Eur. J. 2023; e202300318
  • 13 Painter RM, Pearson DM, Waymouth RM. Angew. Chem. Int. Ed. 2010; 49: 9456
  • 14 Chung K, Banik SM, De Crisci AG, Pearson DM, Blake TR, Olsson JV, Ingram AJ, Zare RN, Waymouth RM. J. Am. Chem. Soc. 2013; 135: 7593
  • 15 Jäger M, Hartmann M, de Vries JG, Minnaard AJ. Angew. Chem. Int. Ed. 2013; 52: 7809
  • 16 Eisink NN. H. M, Lohse J, Witte MD, Minnaard AJ. Org. Biomol. Chem. 2016; 14: 4859
  • 17 Reintjens NR. M, Yakovlieva L, Marinus N, Hekelaar J, Nuti F, Papini AM, Witte MD, Minnaard AJ, Walvoort MT. C. Eur. J. Org. Chem. 2022; 2022: e202200677
  • 18 Wan IC, Hamlin TA, Eisink NN. H. M, Marinus N, Boer C, Vis CA, Codée JD. C, Witte MD, Minnaard AJ, Bickelhaupt FM. Eur. J. Org. Chem. 2021; 2021: 632
  • 19 Chung K, Waymouth RM. ACS Catal. 2016; 6: 4653
  • 20 Marinus N, Walvoort MT. C, Witte MD, Minnaard AJ, van Dijk HM. In Carbohydrate Chemistry: Proven Synthetic Methods, Vol. 5, Chap. 16 Wrodnigg T. M., Stütz A., CRC Press: Boca Raton, 2021
  • 21 William JM, Kuriyama M, Onomura O. Adv. Synth. Catal. 2014; 356: 934
  • 22 Feng L, Zhang S, Sun X, Dong A, Chen Q. J. Mater. Sci. 2018; 53: 15025
  • 23 Maki T, Iikawa S, Mogami G, Harasawa H, Matsumura Y, Onomura O. Chem. Eur. J. 2009; 15: 5364
  • 24 William JM, Kuriyama M, Onomura O. RSC Adv. 2013; 3: 19247
  • 25 Muramatsu W. Org. Lett. 2014; 16: 4846
  • 26 Kaspar M, Kudova E. J. Org. Chem. 2022; 87: 9157
  • 27 Zhang J, Eisink NN. H. M, Witte MD, Minnaard AJ. J. Org. Chem. 2019; 84: 516
  • 28 Marinus N, Tahiri N, Duca M, Mouthaan LM. C. M, Bianca S, van den Noort M, Poolman B, Witte MD, Minnaard AJ. Org. Lett. 2020; 22: 5622
  • 29 Zhang J, Reintjens NR. M, Dhineshkumar J, Witte MD, Minnaard AJ. Org. Lett. 2022; 24: 5339
  • 30 Reintjens NR. M, Witte MD, Minnaard AJ. Org. Biomol. Chem. 2023; 21: 5098
  • 31 Ahmadian-Moghaddam M, Reintjens NR. M, Witte MD, Minnaard AJ. Eur. J. Org. Chem. 2023; 26: e202300281
  • 32 ten Brink G.-J, Arends IW. C. E, Hoogenraad M, Verspui G, Sheldon RA. Adv. Synth. Catal. 2003; 345: 1341
  • 33 Conley NR, Labios LA, Pearson DM, McCrory CC. L, Waymouth RM. Organometallics 2007; 26: 5447
  • 34 Bailie DS, Clendenning GM. A, McNamee L, Muldoon MJ. Chem. Commun. 2010; 46: 7238
  • 35 Lybaert J, Tehrani KA, De Wael K. Electrochim. Acta 2017; 247: 685
  • 36 Amatore C, Cammoun C, Jutand A. Synlett 2007; 2173
  • 37 Dornan LM, Muldoon MJ. Catal. Sci. Technol. 2015; 5: 1428
  • 38 Vu ND, Guicheret B, Duguet N, Métay E, Lemaire M. Green Chem. 2017; 19: 3390
  • 39 Wang H, Vu ND, Chen G.-R, Métay E, Duguet N, Lemaire M. Green Chem. 2021; 23: 1154
  • 40 Because of the low solubility of 1 in acetonitrile, we used a 9:1 (v/v) mixture of acetonitrile and water.
  • 41 To a stock solution of methyl α-d-glucopyranoside (1; 45 mg, 0.23 mmol, 1 equiv) and BQ (26 mg, 0.24 mmol, 1.05 equiv) in MeOH (0.1 M) or 9:1 MeCN–H2O (0.1 M) was added catalyst 3 (5 mg, 5 μmol, 2 mol%) or 4 (2 mg, 5 μmol, 2 mol%), and the mixture was stirred for 24 h at rt under air. A portion of the mixture was diluted with CD3OD and analyzed by 1H NMR. The conversion was calculated by dividing the product integral by the sum of the product and starting material integrals. The TON was calculated by dividing the conversion by the mol% [Pd]. The TOF was calculated by using the conversion after 0.5 h by dividing the TON by the reaction time.
  • 42 Kütt A, Tshepelevitsh S, Saame J, Lõkov M, Kaljurand I, Selberg S, Leito I. Eur. J. Org. Chem. 2021; 2021: 1407
  • 43 Miguel EL. M, Silva PL, Pliego JR. J. Phys. Chem. B 2014; 118: 5730
  • 44 Compounds 6–16; General ProcedureBQ (114 mg, 1.05 mmol, 1.05 equiv), neocuproine (10.5 mg, 50 μmol, 5 mol%), and Pd(OAc)2 (11.2 mg, 50 μmol, 5 mol%) were added to a solution of the appropriate substrate (1.0 mmol, 1 equiv) in MeOH (0.2 M). The reactions were monitored by 1H NMR analysis of a 50 μL portion of the reaction mixture diluted with CD3OD. After stirring overnight, the mixture was concentrated in vacuo and the residue was dissolved in H2O (15 mL; Milli-Q), and the solution was washed with Et2O (2 × 30 mL). The aqueous layer was filtered twice through a 1.0 μm pore-size syringe filter and once through a 0.45 μm pore-size syringe filter, then concentrated in vacuo.
  • 45 Characterization data for 8: amorphous solid; yield: 0.14 g, 0.69 mmol (77%). 1H NMR (400 MHz, CD3OD): d = 5.39 (d, J = 4.2 Hz, 1 H), 4.20–4.14 (m, 1 H), 3.95 (dt, J = 12.4, 6.2 Hz, 1 H), 3.89–3.77 (m, 3 H), 2.88 (ddd, J = 13.9, 4.6, 1.1 Hz, 1 H), 2.43 (dd, J = 13.9, 0.9 Hz, 1 H), 1.15 (dd, J = 12.2, 6.2 Hz, 6 H). 13C NMR (101 MHz, CD3OD): d = 207.6, 97.9, 76.6, 74.2, 70.0, 62.6, 47.1, 23.5, 21.4. HRMS(ESI–): m/z [M–H]– calcd for C9H15O5: 203.0925; found: 203.0925.
  • 46 Characterization data for 11: amorphous solid; yield: 0.15 g, 0.85 mmol (85%) [+ 20 mg (0.11 mmol) starting material]. 1H NMR (400 MHz, CD3OD): δ = 4.99 (d, J = 4.4 Hz, 1 H), 4.42 (dd, J = 4.4, 1.5 Hz, 1 H), 3.89 (dd, J = 9.4, 1.4 Hz, 1 H), 3.76–3.68 (m, 1 H), 3.38 (s, 4 H), 1.39 (d, J = 6.2 Hz, 3 H). 13C NMR (101 MHz, CD3OD): δ = 206.5, 103.6, 78.8, 76.1, 72.0, 55.7, 18.9. HRMS(ESI): m/z [M–H] calcd for C7H11O5: 175.0612; found: 175.0612.
  • 47 Characterization data for 12: amorphous solid; yield: 0.15 g 0.74 mmol (85%) [+ starting material: 15 mg (7 μmol)]. 1H NMR (400 MHz, CD3OD): δ = 5.11 (d, J = 4.2 Hz, 1 H), 4.49 (dd, J = 4.1, 1.2 Hz, 1 H), 4.45 (d, J = 9.8 Hz, 1 H), 4.08 (d, J = 9.8 Hz, 1 H), 3.44 (d, J = 4.8 Hz, 3 H). 13C NMR (101 MHz, CD3OD) δ = 205.4, 104.3, 76.0, 75.0, 75.0, 56.2. HRMS (ESI): m/z [M–H] calcd for C7H9O7: 205.0354; found: 205.0354.
  • 48 Characterization data for 13: amorphous solid; yield: 0.22 g, 0.73 mmol (73%). 1H NMR (400 MHz, CD3OD): δ = 5.08 (d, J = 4.3 Hz, 1 H), 4.41 (dd, J = 4.2, 1.2 Hz, 1 H), 4.27 (dd, J = 9.7, 1.2 Hz, 1 H), 4.06–3.92 (m, 2 H), 3.68 (ddd, J = 9.7, 4.4, 2.0 Hz, 1 H), 3.43 (s, 3 H), 0.98 (s, 9 H), 0.16 (s, 6 H). 13C NMR (101 MHz, CD3OD): δ = 207.0, 103.7, 76.8, 76.0, 73.2, 63.9, 55.6, 26.4, –5.1, –5.2. HRMS (ESI): m/z [M + Na]+ calcd for C13H26NaO6Si: 329.1391; found: 329.1391.
  • 49 Eisink NN. H. M, Witte MD, Minnaard AJ. ACS Catal. 2017; 7: 1438
  • 50 Zhiyuan Z, Shaoqiang H, Zhaolan Z, Yanning SU, Yan RE. N. WO 2016041470 2016
  • 51 Balkanski S. Pharmacia (Sofia, Bulg.) 2021; 68: 591
  • 52 Characterization data for 16: colorless oil; yield: 0.25 g, 0.62 mmol (62%). 1H NMR (400 MHz, CD3OD): δ = 7.42–7.35 (m, 3 H), 7.09 (d, J = 8.6 Hz, 2 H), 6.79 (d, J = 8.6 Hz, 2 H), 4.39 (d, J = 10.0 Hz, 1 H), 4.23 (s, 2 H), 4.11–3.90 (m, 5 H), 3.82 (dd, J = 12.1, 4.7 Hz, 1 H), 3.49 (ddd, J = 10.0, 4.8, 1.9 Hz, 1 H), 1.35 (t, J = 7.0 Hz, 4 H). 13C NMR (101 MHz, CD3OD): δ = 208.4, 158.9, 140.1, 139.3, 135.0, 132.8, 131.7, 130.8, 130.3, 128.0, 115.4, 85.2, 84.7, 78.6, 74.0, 64.4, 62.9, 39.2, 15.2. HRMS(ESI): m/z [M–H] calcd for C21H22ClO6: 405.1110 and 407.1081; found: 405.1105 and 407.1076.
  • 53 Nakamura K, Zhu S, Komatsu K, Hattori M, Iwashima M. Biol. Pharm. Bull. 2019; 42: 417
  • 54 Characterization data for 20: isolated as an oil, together with 21; yield: 51 mg, 0.11 mmol (48%). 1H NMR (400 MHz, CD3OD): δ = 8.13 (s, 1 H), 8.03–7.96 (m, 1 H), 7.41–7.31 (m, 2 H), 6.91–6.82 (m, 3 H), 5.80 (s, 1 H), 4.79 (d, J = 9.3 Hz, 1 H), 4.09–3.92 (m, 2 H), 3.91–3.85 (m, 1 H), 3.20 (s, 3 H). 13C NMR (101 MHz, CD3OD): δ = 177.8, 173.5, 162.9, 158.7, 156.2, 154.2, 131.3, 127.9, 125.8, 124.0, 117.9, 117.5, 116.2, 110.1, 87.6, 86.1, 83.3, 74.1, 59.6, 52.6. HRMS (ESI): m/z [M–H] calcd for C22H21O10 [M+H]+: 445.1129; found: 445.1124.
  • 55 Characterization data for 23: isolated as an oil together with 24; yield: 96 mg, 0.32 mmol (32%). 1H NMR (400 MHz, CD3OD): δ = 8.44 (d, J = 2.7 Hz, 1 H), 8.10 (dd, J = 9.0, 2.8 Hz, 1 H), 6.94 (d, J = 9.0 Hz, 1 H), 4.82 (d, J = 10.0 Hz, 1 H), 4.54 (dd, J = 10.0, 1.6 Hz, 1 H), 4.44 (dd, J = 10.0, 1.5 Hz, 1 H), 3.95 (dd, J = 12.3, 1.9 Hz, 1 H), 3.84 (dd, J = 12.3, 4.8 Hz, 1 H), 3.55 (ddd, J = 10.0, 4.8, 2.0 Hz, 1 H). 13C NMR (101 MHz, CD3OD): δ = 208.4, 163.0, 141.9, 127.3, 126.4, 126.0, 116.6, 84.8, 78.8, 78.1, 74.0, 62.9. HRMS (ESI): m/z [M–H] calcd for C12H12NO8: 298.0568; found: 298.0563.
  • 56 Characterization data for 24: isolated as an oil together with 23; yield: 26 mg, 90 μmol (9%). 1H NMR (400 MHz, CD3OD): δ = 8.22 (d, J = 2.8 Hz, 1 H), 8.08 (dd, J = 8.9, 2.8 Hz, 1 H), 6.88 (d, J = 9.1 Hz, 1 H), 5.37 (s, 1 H), 4.43 (d, J = 9.3 Hz, 1 H), 4.02 (d, J = 10.3 Hz, 1 H), 3.94–3.79 (m, 2 H), 3.68 (t, J = 9.4 Hz, 1 H). 13C NMR (101 MHz, CD3OD): δ = 202.1, 162.0, 141.8, 126.2, 125.2, 124.6, 115.5, 82.7, 81.3, 78.6, 76.2, 62.7. HRMS (ESI): m/z [M–H] calcd for C12H12NO8: 298.0568; found: 298.0564.

Zoom Image
Scheme 1 Palladium-catalyzed oxidation. DCBQ = 2,6-dichloro-1,4-benzoquinone, BQ = benzoquinone, neocuproine = 2,9-dimethyl-1,10-phenanthroline.
Zoom Image
Figure 1 Oxidation of gluco-configured substrates. Reaction conditions: substrate (1 mmol), Pd(OAc)2 (0.05 equiv), neocuproine (0.05 equiv), BQ (1.05 equiv), 0.2 M in MeOH, 50 °C, 18 h. a BQ (1.5 equiv). b After 4 h, an additional 0.5 equivalents of BQ were added. c Yield reported in the literature.[15] [29] [49] [50]
Zoom Image
Scheme 2 Reaction conditions a: Pd(OAc)2 (0.05 equiv), neocuproine (0.05 equiv), BQ (1.05 equiv), 0.2 M in MeOH, 50 °C. Isolated yields are reported. a Yield reported in the literature.[49]